Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis | SpringerLink
Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study | BMC Musculoskeletal Disorders | Full Text
Should You Get the COVID-19 Vaccine If You Take Rituximab?
Eficiency of Different Doses of Rituximab in Rheumatoid Arthritis | Reumatología Clínica
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study
PDF) Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration
Algorithm for the use of rituximab in patients with RA. Broken line... | Download Scientific Diagram
Rituximab Biosimilar Truxima Now Available for Rheumatoid Arthritis - MPR
Arthritis News: Lower Dose of Rituximab for RA Treatment Explored
VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression | 2 Minute Medicine
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology
Protocol of rituximab dosing and administration. | Download Scientific Diagram
Lessons for rituximab therapy in patients with rheumatoid arthritis - The Lancet Rheumatology
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine
Rituximab in MS | Experimental MS Treatments | Multiple Sclerosis News Today
Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study - Consumer Health News | HealthDay
RA | RITUXAN® (rituximab) Infusion Steps & Resources
Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens | HTML | Acta Dermato-Venereologica
Rituximab protocols | Download Table
RA | RITUXAN® (rituximab) Infusions & Dosing Schedule
Rituximab Infusion Dosing | RIABNI™ (rituximab-arrx)
